CryoCell Financial Statements From 2010 to 2026

CCEL Stock  USD 3.40  0.01  0.29%   
CryoCell International's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing CryoCell International's valuation are provided below:
Gross Profit
24.5 M
Profit Margin
(0.01)
Market Capitalization
27.4 M
Enterprise Value Revenue
1.1605
Revenue
31.7 M
There are over one hundred nineteen available fundamental signals for CryoCell International, which can be analyzed over time and compared to other ratios. We recommend to validate CryoCell International's prevailing fundamental drivers against the all of the trends between 2010 and 2026. Market Cap is expected to rise to about 29.9 M this year, although Enterprise Value will most likely fall to about 38.2 M.

CryoCell International Total Revenue

19.47 Million

Check CryoCell International financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among CryoCell International's main balance sheet or income statement drivers, such as Depreciation And Amortization of 632.3 K, Selling General Administrative of 11.5 M or Total Revenue of 19.5 M, as well as many indicators such as Price To Sales Ratio of 1.11, Dividend Yield of 0.0674 or Days Sales Outstanding of 79.7. CryoCell financial statements analysis is a perfect complement when working with CryoCell International Valuation or Volatility modules.
  
Build AI portfolio with CryoCell Stock
Check out the analysis of CryoCell International Correlation against competitors.
For more information on how to buy CryoCell Stock please use our How to buy in CryoCell Stock guide.

CryoCell International Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets74.5 M71 M40.7 M
Slightly volatile
Other Current Liabilities2.6 M5.1 M3.6 M
Slightly volatile
Total Current Liabilities23.9 M22.8 M15.5 M
Slightly volatile
Property Plant And Equipment Net26.4 M25.1 M8.8 M
Slightly volatile
Accounts Payable3.5 M3.3 M1.7 M
Slightly volatile
Cash348.5 K366.9 K3.5 M
Slightly volatile
Non Current Assets Total60.3 M57.5 M28.2 M
Slightly volatile
Non Currrent Assets OtherM1.9 M3.8 M
Slightly volatile
Cash And Short Term Investments5.3 M3.8 M4.6 M
Pretty Stable
Net Receivables8.8 M8.4 M5.4 M
Slightly volatile
Common Stock Shares Outstanding7.8 M7.3 M8.6 M
Slightly volatile
Liabilities And Stockholders Equity74.5 M71 M40.7 M
Slightly volatile
Non Current Liabilities Total73.1 M69.6 M34.6 M
Slightly volatile
Other Stockholder Equity21.8 M22.6 M19.4 M
Very volatile
Total Liabilities97 M92.4 M50.1 M
Slightly volatile
Total Current Assets10.7 M13.5 M12.2 M
Slightly volatile
Intangible Assets942.9 K992.5 K2.5 M
Pretty Stable
Short and Long Term Debt Total2.7 M2.9 M5.9 M
Slightly volatile
Other Current Assets9.7 M9.3 M2.5 M
Slightly volatile
Short Term Debt1.9 M3.1 MM
Slightly volatile
Short Term Investments3.6 M3.4 M1.2 M
Slightly volatile
Common Stock136.8 K171.1 K134.7 K
Slightly volatile
Other Liabilities45.9 M43.7 M25.9 M
Slightly volatile
Other Assets28.6 M27.2 M15.6 M
Slightly volatile
Long Term Debt5.5 M9.6 M5.7 M
Slightly volatile
Property Plant Equipment17.2 M16.3 M6.4 M
Slightly volatile
Common Stock Total Equity140.6 K156.8 K131.7 K
Slightly volatile
Capital Surpluse34.8 M42.1 M33.4 M
Slightly volatile
Non Current Liabilities Other788.3 K829.8 K6.7 M
Slightly volatile
Inventory349.5 K367.9 K1.6 M
Very volatile
Short and Long Term Debt2.5 M4.2 MM
Slightly volatile
Capital Stock157.2 K171 K142.9 K
Slightly volatile

CryoCell International Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization632.3 K864.2 K648.7 K
Slightly volatile
Selling General Administrative11.5 M21.3 M14.2 M
Slightly volatile
Total Revenue19.5 M36.3 M25.4 M
Slightly volatile
Gross Profit13.9 M27.8 M18.4 M
Slightly volatile
Other Operating Expenses18.9 M35.7 M23.4 M
Slightly volatile
Cost Of Revenue5.7 M8.5 MM
Slightly volatile
Total Operating Expenses28.6 M27.3 M17.4 M
Slightly volatile
Research Development263.6 K432.7 K271.6 K
Slightly volatile
Interest Expense1.2 M2.4 M1.4 M
Slightly volatile
Reconciled DepreciationM1.2 M709 K
Slightly volatile

CryoCell International Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation1.7 M1.6 M818.3 K
Slightly volatile
Other Non Cash Items11.3 M10.8 M3.8 M
Slightly volatile
Capital Expenditures251.8 K265 K2.2 M
Slightly volatile
Total Cash From Operating Activities3.2 M6.3 M5.1 M
Slightly volatile
End Period Cash Flow348.5 K366.9 K3.5 M
Slightly volatile
Begin Period Cash Flow612.8 K645.1 K3.9 M
Pretty Stable
Stock Based Compensation630.7 K898.3 K680 K
Very volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.111.172.1993
Slightly volatile
Dividend Yield0.06740.09060.1528
Slightly volatile
Days Sales Outstanding79.795.9275.1943
Slightly volatile
Operating Cash Flow Per Share0.640.610.623
Slightly volatile
Average Payables2.2 M2.1 M1.5 M
Slightly volatile
Stock Based Compensation To Revenue0.02780.02810.0272
Pretty Stable
Capex To Depreciation0.140.151.8609
Pretty Stable
EV To Sales1.211.282.2552
Slightly volatile
Inventory Turnover9.1216.2410.6228
Slightly volatile
Days Of Inventory On Hand22.123.2674.6803
Pretty Stable
Payables Turnover2.812.964.5509
Very volatile
Sales General And Administrative To Revenue0.580.620.5765
Slightly volatile
Average Inventory582.6 K613.2 KM
Pretty Stable
Research And Ddevelopement To Revenue0.0130.01370.0383
Slightly volatile
Capex To Revenue0.0080.00840.0766
Pretty Stable
Cash Per Share0.40.370.5348
Very volatile
POCF Ratio5.015.2814.5324
Slightly volatile
Capex To Operating Cash Flow0.0460.04840.3374
Pretty Stable
Days Payables Outstanding10016390.5432
Slightly volatile
EV To Operating Cash Flow6.987.3514.869
Slightly volatile
Intangibles To Total Assets0.03280.04090.069
Pretty Stable
Current Ratio0.650.681.0118
Slightly volatile
Receivables Turnover7.465.035.1868
Pretty Stable
Capex Per Share0.02440.02570.2669
Slightly volatile
Average ReceivablesM5.7 MM
Slightly volatile
Revenue Per Share3.73.523.0487
Slightly volatile
Interest Debt Per Share0.150.160.8123
Pretty Stable
Debt To Assets0.05670.05970.178
Slightly volatile
Graham Number0.921.551.6206
Very volatile
Operating Cycle17.2918.2124
Pretty Stable
Days Of Payables Outstanding10016390.5432
Slightly volatile
Price To Operating Cash Flows Ratio5.015.2814.5324
Slightly volatile
Quick Ratio0.630.660.9191
Slightly volatile
Cash Ratio0.01760.01850.3735
Slightly volatile
Operating Cash Flow Sales Ratio0.160.17360.2019
Very volatile
Days Of Inventory Outstanding22.123.2674.6803
Pretty Stable
Days Of Sales Outstanding79.795.9275.1943
Slightly volatile
Fixed Asset Turnover1.231.311.6091
Slightly volatile
Price Cash Flow Ratio5.015.2814.5324
Slightly volatile
Debt Ratio0.05670.05970.178
Slightly volatile
Price Sales Ratio1.111.172.1993
Slightly volatile
Asset Turnover0.680.460.8681
Slightly volatile
Gross Profit Margin0.560.690.7209
Slightly volatile

CryoCell International Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap29.9 M28.9 M46.2 M
Pretty Stable
Enterprise Value38.2 M40.2 M49.4 M
Slightly volatile

CryoCell Fundamental Market Drivers

CryoCell Upcoming Events

27th of February 2024
Upcoming Quarterly Report
View
30th of November 2023
Next Fiscal Quarter End
View

About CryoCell International Financial Statements

CryoCell International investors utilize fundamental indicators, such as revenue or net income, to predict how CryoCell Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue11.2 M6.8 M
Total Revenue36.3 M19.5 M
Cost Of Revenue8.5 M5.7 M
Stock Based Compensation To Revenue 0.03  0.03 
Sales General And Administrative To Revenue 0.62  0.58 
Research And Ddevelopement To Revenue 0.01  0.01 
Capex To Revenue 0.01  0.01 
Revenue Per Share 3.52  3.70 
Ebit Per Revenue 0.01  0.01 

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether CryoCell International is a strong investment it is important to analyze CryoCell International's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact CryoCell International's future performance. For an informed investment choice regarding CryoCell Stock, refer to the following important reports:
Check out the analysis of CryoCell International Correlation against competitors.
For more information on how to buy CryoCell Stock please use our How to buy in CryoCell Stock guide.
You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CryoCell International. Projected growth potential of CryoCell fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive CryoCell International assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth
(0.31)
Dividend Share
0.65
Earnings Share
(0.06)
Revenue Per Share
3.933
Quarterly Revenue Growth
(0.03)
Investors evaluate CryoCell International using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating CryoCell International's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause CryoCell International's market price to deviate significantly from intrinsic value.
It's important to distinguish between CryoCell International's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding CryoCell International should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, CryoCell International's market price signifies the transaction level at which participants voluntarily complete trades.